PharmEasy Unlisted Share Price
PharmEasy unlisted share price is ₹7.5 per share (indicative, as of 17 Oct 2026). Minimum ticket ₹25,000 (lot of 3335 shares), the same for every company. Sector: New-age. Status: unlisted, no DRHP on record.
All unlisted share prices: dated indicative prices for every company the desk tracks.
Updated 17 Oct 2026, 22:10 IST. Dated dealer references.
BuyUnlistedShares tracks 230 unlisted companies with dated prices; PharmEasy’s indicative price is ₹7.5 per share as of 17 Oct 2026, a lot of 3335 shares.
Key facts
- Indicative price
- ₹7.5 per share
- Price as of
- 17 Oct 2026
- Minimum investment
- ₹25,000
- Lot size
- 3,335 shares
- Sector
- New-age
- Listing status
- Unlisted
- Settlement
- Demat to demat; terms agreed in writing for each deal
- Last updated
- 17 Oct 2026, 22:10 IST
Indicative and dated. BuyUnlistedShares deals as principal.
Buying at a glance
- Minimum ticket
- ₹25,000
- Price shown
- Indicative, dated 17 Oct 2026
- Delivery
- Shares are credited to your demat account
In plain words
- Lock-in if it lists
- Shares bought before an IPO are generally locked in for six months from the IPO allotment date under SEBI rules. The issue documents set the exact terms.
- Demat
- Yes. ISIN INE0DJ201029: the shares sit in your own demat account and move demat to demat through NSDL or CDSL.
- IPO status
- Unlisted. No DRHP on record.
Facts only, not a rating or a recommendation.
Compare it against the full unlisted share price list: every company the desk quotes, each with a dated indicative price.
Indicative move: +33.9% over 3 months · +11.1% over 1 year.
Key figures
| Market cap | ₹9,538 Cr |
|---|---|
| Minimum investment | ₹25,000 |
| Lot size | 3335 |
| P/E ratio | — |
| ROE | — |
| Book value | ₹1.75 |
| Face value | ₹1 |
| 52-week high | ₹10 |
| 52-week low | ₹6 |
| ISIN | INE0DJ201029 |
| Dividend yield | — |
Financials (₹ Cr)
| Metric | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | 6,644 | 5,664 | 5,872 |
| PAT | -5,211 | -2,533 | -1,572 |
| EPS (₹) | -9.00 | -3.02 | -1.05 |
About the company
PharmEasy is the consumer-facing brand operated under API Holdings Limited, one of India's largest digital healthcare and e-pharmacy platforms. The business connects patients, pharmacies, diagnostic labs, and hospitals through a single technology layer, allowing users to order prescription and over-the-counter medicines, book diagnostic tests, schedule teleconsultations, and access health…
Prices shown are indicative and dated. Unlisted shares are illiquid and values can move sharply.
Registered in Mumbai, Maharashtra.
Registry
- ISIN: INE0DJ201029
- Depository: NSDL & CDSL
- Listed at: Unlisted
- Price as of: 17 Oct 2026
Company facts
| CIN | U60100MH2019PLC323444 |
|---|---|
| Incorporated | 2019 |
| ISIN | INE0DJ201029 |
| Face value | ₹1 |
| Registered office | 1st Floor, E-Shape Building, Ashok Silk Mills Compound, 202, L.B.S Marg, Ghatkopar (West), Mumbai 400086, Maharashtra, India |
| Lot size | 3335 shares |
| Minimum units | 1260 |
| DRHP | Not filed |
Financial statements (₹ Cr)
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 vs FY25 |
|---|---|---|---|---|---|---|
| Revenue | 5,728.82 | 6,643.94 | 5,664.29 | 5,872.16 | 6,618.5 | +12.7% |
| EBITDA | — | −1,421 | −646 | −661 | 38 | loss to profit |
| Profit before tax | — | −5,196 | −2,522 | −1,517 | −456 | +69.9% |
| Profit after tax | −3,992.5 | −5,211.44 | −2,533.4 | −1,572.39 | −520 | +66.9% |
| EPS (₹) | — | −9 | −3.02 | −1.05 | −0.74 | +29.5% |
| Operating margin | — | — | −11.4% | −11.3% | — | — |
| Net margin | — | — | −44.7% | −26.8% | — | — |
| Share capital | — | — | 624.04 | 651.67 | — | — |
| Reserves & surplus | — | — | 1,564.75 | 2,308.92 | — | — |
| Net worth | — | — | 2,188.79 | 2,960.59 | — | — |
| Trade receivables | — | — | 706.21 | 669.51 | — | — |
| Trade payables | — | — | 412.91 | 426.71 | — | — |
| Cash from operations | — | — | −61.14 | −223.53 | — | — |
| Cash from investing | — | — | −1,260.95 | 774.96 | — | — |
| Cash from financing | — | — | 1,456.83 | −759.91 | — | — |
| Net cash generated | — | — | 134.75 | −208.48 | — | — |
Key ratios and valuation
| Measure | Value | Basis |
|---|---|---|
| Indicative price | ₹7.5 | dealer reference, 17 Oct 2026 |
| Market cap | ₹9,538 Cr | as recorded |
| P/E | — | loss-making, n/a |
| P/B | 4.29x | price ÷ book value ₹1.75 |
| EPS | ₹−0.74 | per share, FY26 |
| Book value | ₹1.75 | per share, latest books |
| RoE | — | |
| Debt / equity | 0.68 | latest balance sheet |
| Dividend yield | — | |
| Face value | ₹1 | per share |
| 52-week range | ₹6 – ₹10 | 318 dated quotes, last 12 months |
| Shares outstanding | — | not meaningful |
Management and promoters
| Name | Designation | Experience |
|---|---|---|
| Siddharth Shah | Co-Founder, Managing Director & CEO | — |
| Dharmil Sheth | Co-Founder, Whole-time Director | — |
| Dr. Dhaval Shah | Co-Founder, Whole-time Director | — |
| Harsh Parekh | Co-Founder, Whole-time Director | — |
| Hardik Dedhia | Co-Founder | — |
Business model
API Holdings Limited operates a technology-enabled healthcare platform through its PharmEasy marketplace and group businesses rather than as a single-channel pharmacy. The annual report describes product sales on the PharmEasy marketplace, technology-powered distribution to chemists and institutions through Retailio 1P, and hospital distribution through Aknamed. Retailio 1P procures pharmaceuticals, OTC products, surgical goods and consumables from pharmaceutical companies, then supplies local chemists and institutional customers directly or through Retailio technology.
The group's diagnostics activity uses Thyrocare laboratories and offers tests through collection centres, home collection and online booking; PharmEasy Labs is its marketplace-facing diagnostics brand. Other services include fulfilment for pharmaceutical and OTC products sold on the marketplace and technology or software services for doctors and pharmacies. Retailio's app and web platform connect wholesalers and pharmacies for procurement.
The disclosed model therefore combines marketplace commerce, B2B distribution, institutional supply, diagnostics and healthcare software and fulfilment services.
News and insights
- PharmEasy 2026: Docon Sells Thyrocare Stake (13 Oct 2026)
- PharmEasy Unlisted Share Price Drops 11.7% in September 2026 (5 Oct 2026)
- PharmEasy Just Sold Another Slice of Thyrocare (18 Aug 2026)
- PharmEasy Repays 10% of Thyrocare Loan: ₹1,080 Cr Still at Risk - What It Means (1 May 2026)
Corporate actions and events
| Date | Type | Detail | Ratio / amount | Source |
|---|---|---|---|---|
| Sep 2025 | Funding | Raised Rs 1,700 crore via NCDs, pledging ~61% of Thyrocare — API Holdings raised about Rs 1,700 crore through redeemable non-convertible debentures to refinance an earlier NCD liability, with subsidiary Docon Technologies pledging roughly 61% (about 3.23 crore shares) of listed… | — | Desk note |
| Aug 2025 | Other | Leadership change: Siddharth Shah steps down as CEO; Rahul Guha takes over — Co-founder Siddharth Shah stepped down as chief executive officer of PharmEasy/API Holdings, with Rahul Guha, previously managing director and CEO of group company Thyrocare, taking over as CEO. | — | Desk note |
| rep 2025 | Other | FY25 results: revenue roughly flat at ~Rs 6,010 crore as company prioritised margins — For FY25 API Holdings reported consolidated revenue of around Rs 6,010 crore, broadly flat year-on-year, while narrowing losses as management focused on improving gross margins and cutting costs across the PharmEasy… | — | Desk note |
| Undated | Other | FY26 results: first-ever positive EBITDA of Rs 62.5 crore (reported May 2026) — API Holdings reported consolidated FY26 revenue of about Rs 6,869 crore, up roughly 14% year-on-year, and posted its first full-year positive EBITDA of around Rs 62.5 crore, reversing an EBITDA loss of about Rs 231… | — | Desk note |
Reports and filings
No filings uploaded yet.
Annual reports
- PharmEasy annual report 2024-25 standalone (PDF)
- PharmEasy annual report 2024-25 consolidated (PDF)
- PharmEasy annual report 2024-25 board's report (PDF)
- PharmEasy annual report 2024-25 annual return (PDF)
Frequently asked questions
What does PharmEasy do?
PharmEasy is the consumer brand of API Holdings Limited, a digital healthcare and e-pharmacy platform. It lets users order prescription and over-the-counter medicines, book diagnostic and lab tests, access teleconsultations, and buy health products online, and it also operates in pharmaceutical distribution and diagnostics, including the Thyrocare lab network.
Is PharmEasy listed on the stock exchange, and how can someone buy its unlisted shares?
No. PharmEasy's parent, API Holdings Limited, is not listed on the NSE or BSE. It filed draft IPO papers and later withdrew them, so its shares remain unlisted. Transfers happen demat-to-demat through NSDL/CDSL depository participants.
What determines PharmEasy's indicative unlisted share price?
The indicative price reflects negotiated transactions between buyers and sellers in the private secondary market rather than an exchange quote. It can be influenced by the company's financial performance, fundraising rounds such as rights issues, debt levels, demand and supply among unlisted investors, and overall sentiment toward digital healthcare. The figure is indicative only and may differ from one platform to another.
What are the key fundamentals of PharmEasy's unlisted shares?
PharmEasy's shares are issued under API Holdings Limited, with ISIN INE0DJ201029, CIN U60100MH2019PLC323444, and a face value of ₹1 per share. The company was incorporated in 2019 and is registered in Mumbai, Maharashtra. These are factual reference details and not a recommendation to transact.
Can I buy PharmEasy unlisted shares?
PharmEasy is not listed on a stock exchange, so its shares change hands off market, between existing holders and buyers. To buy through BuyUnlistedShares, send an enquiry with the quantity you have in mind. You need a demat account (NSDL or CDSL) and your PAN; the minimum ticket is ₹25,000, the same for every company on this site.
How is the PharmEasy unlisted share price set?
Unlisted shares have no exchange order book, so the price is set by demand and supply between buyers and sellers in the off-market (over-the-counter) market, and it moves with company news such as funding rounds, results and IPO filings. The ₹7.5 on this page is an indicative reference dated 17 Oct 2026. The price for an actual deal is confirmed in writing before you pay.
How are PharmEasy shares delivered?
Demat to demat. The shares (ISIN INE0DJ201029) are credited to your own demat account through NSDL or CDSL, and you pay only into the Gayatri Financial Synergy LLP company bank account, never to an individual.
Can I sell my PharmEasy unlisted shares?
Send a sell enquiry with the company and the quantity you hold. A person on the desk comes back to you, and if a deal is agreed, the shares move demat to demat from your account.
What is the PharmEasy unlisted share price today?
The indicative over-the-counter reference price is ₹7.5 per share as of 17 Oct 2026. It is a dated dealer reference, refreshed every working day.
Is PharmEasy listed on a stock exchange?
Not yet. PharmEasy changes hands in the unlisted market, over the counter and settle into your demat account through NSDL and CDSL.
What is the minimum investment in PharmEasy?
The minimum ticket is ₹25,000, the same for every company on the site.
What is the ISIN of PharmEasy?
INE0DJ201029. Holdings are settled in demat form through NSDL and CDSL.
How do I buy PharmEasy unlisted shares?
Send an enquiry with the quantity you have in mind. The desk replies with a dated quote, the paperwork list and the demat steps, and the shares settle demat to demat into your own account.
Is there a lock-in if PharmEasy lists?
Pre-IPO shareholders other than promoters are generally locked in for six months from the date of IPO allotment under SEBI ICDR regulation 17. The final offer document sets the exact terms.
Sources
- PharmEasy annual report 2024-25 standalone · FY 2024-25 standalone · apiholdings.in
- PharmEasy annual report 2024-25 consolidated · FY 2024-25 consolidated · apiholdings.in
- PharmEasy annual report 2024-25 board's report · FY 2024-25 board's report · apiholdings.in
- PharmEasy annual report 2024-25 annual return · FY 2024-25 annual return · apiholdings.in
- BuyUnlistedShares indicative price series for PharmEasy, dated daily · since 12 Sep 2025 (344 dated quotes) · buyunlistedshares.com
How to cite this page: BuyUnlistedShares, “PharmEasy unlisted share price”, https://buyunlistedshares.com/unlisted-shares/pharmeasy, as of 17 Oct 2026.
Other New-age unlisted shares
- Oravel Stays (OYO Rooms) · ₹21.5
- PhonePe Limited · ₹19,968
- PhonePe Limited · ₹19,968
- Razorpay Software Limited · ₹85.12
- Zepto · ₹29.75
- Zepto · ₹29.75
Enquire to buy PharmEasy · Sell a holding
Indicative reference price, dated. BuyUnlistedShares is India's premium unlisted shares desk, run by Gayatri Financial Synergy LLP. In the market since 2002. Data as of 17 Oct 2026.
Before you buy: guides
- How to evaluate an unlisted company before investing
- How Unlisted Share Prices Are Discovered When There Is No Live Order Book
- The risks of buying unlisted and pre-IPO shares in India
- Unlisted Shares Lock-In Period: What Every Investor Must Know (2026)
- Can an NRI invest in unlisted shares in India?
All unlisted shares · IPO calendar · Research & learning · Send an enquiry · Calculators · Jobs · About · Contact · Privacy · Terms · Disclaimer · Grievance redressal
Guides: Start investing · Evaluate a company · How prices are set · Risks · Lock-in periods · After the IPO · Sell ESOPs · NRI investors · Buybacks · Choosing a platform
BuyUnlistedShares (BUS) · Gayatri Financial Synergy LLP (LLPIN ACU-4678) · SCO-39, 1st Floor, HUDA Market, Sector-7, Faridabad, Haryana 121006 · +91 916-916-59-59
